In NSCLC, epidermal growth factor receptor (EGFR) mutations account for 15–40% of cases of non-squamous type and EGFR inhibitors have been used clinically to treat lung cancer caused by EGFR abnormalities [7]. This evidence concerns the gene EGFR and lung carcinoma.